Apellis Pharmaceuticals, Inc. Common Stock
APLS Real Time Price USDRecent trades of APLS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by APLS's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Dosing regimens Feb. 20, 2024
-
Patent Title: Dosing regimens and related compositions and methods Dec. 19, 2023
-
Patent Title: Methods of treating chronic disorders with complement inhibitors Aug. 01, 2023
-
Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof May. 30, 2023
-
Patent Title: Rnas for complement inhibition Nov. 29, 2022
-
Patent Title: Cell-penetrating compstatin analogs and uses thereof Aug. 09, 2022
-
Patent Title: Combination therapy for c3 inhibition May. 24, 2022
-
Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods Apr. 05, 2022
-
Patent Title: Detection of high risk drusen Apr. 05, 2022
-
Patent Title: Dosing regimens and related compositions and methods Jun. 22, 2021
-
Patent Title: Methods of treating chronic disorders with complement inhibitors May. 25, 2021
-
Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof May. 11, 2021
-
Patent Title: Cell-penetrating compstatin analogs and uses thereof Mar. 09, 2021
-
Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods Dec. 29, 2020
-
Patent Title: Compstatin analogs for treatment of neuropathic pain Jun. 30, 2020
-
Patent Title: Methods of selecting compstatin mimetics Sep. 10, 2019
-
Patent Title: Cell-penetrating compstatin analogs and uses thereof Jun. 04, 2019
-
Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof Nov. 13, 2018
-
Patent Title: Methods of treating chronic disorders with complement inhibitors Aug. 07, 2018
-
Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods Jul. 31, 2018
-
Patent Title: Compstatin analogs for treatment of neuropathic pain Aug. 23, 2016
-
Patent Title: Complement assays and uses thereof Mar. 22, 2016
-
Patent Title: Local complement inhibition for treatment of complement-mediated disorders Nov. 12, 2013
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of APLS in WallStreetBets Daily Discussion
Recent insights relating to APLS
Recent picks made for APLS stock on CNBC
ETFs with the largest estimated holdings in APLS
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view APLS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.